A 1120

TargetMol
Product Code: TAR-T10203
Supplier: TargetMol
CodeSizePrice
TAR-T10203-1mg1mg£101.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10203-2mg2mg£114.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10203-5mg5mg£142.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10203-1mL1 mL * 10 mM (in DMSO)£149.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10203-10mg10mg£189.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10203-25mg25mg£322.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10203-50mg50mg£503.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10203-100mg100mg£687.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
A 1120 is a nonretinoid retinol-binding protein 4 (RBP4) antagonist (Ki: 8.3 nM), which disrupts the interaction between RBP4 and its binding partner transthyretin.
CAS:
1152782-19-8
Formula:
C20H19F3N2O3
Molecular Weight:
392.378
Purity:
0.9947
SMILES:
OC(=O)c1ccccc1NC(=O)N1CCC(CC1)c1ccccc1C(F)(F)F

References

1. Motani A, et al. Identification and characterization of a non-retinoid ligand for retinol-binding protein 4 which lowers serum retinol-binding protein 4 levels in vivo. J Biol Chem. 2009 Mar 20;284(12):7673-80. 2. Dobri N, et al. A1120, a nonretinoid RBP4 antagonist, inhibits formation of cytotoxic bisretinoids in the animal model of enhanced retinal lipofuscinogenesis. Invest Ophthalmol Vis Sci. 2013 Jan 7;54(1):85-95. 3. Xue C, Tian Y, Zhang J, Zhao Y, Zhan J, Fang W, Zhang L. Efficacy of BIBF 1120or BIBF 1120 plus chemotherapy on nasopharyngeal carcinoma in vitro and in vivo.Drug Des Devel Ther. 2016 Mar 15;10:1173-80